Clinical trials: Steroid Refractory
Graft vs Host Disease
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and…
- Trial name
- NCT03474679
- Testing
- Ibrutinib
- Where
- 15 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Acute GvHD
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further…
- Trial name
- ALD518-010 (NCT01530256)
- Testing
- ALD518
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- CSL Behring
Allogeneic Hematopoietic Stem Cell Transplantation
A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
The purpose of this study is to assess the initial activity, tolerability, safety and to identify a recommended dose and regimen of vedolizumab intravenous (IV) administered for treatment of steroid-refractory acute intestinal…
- Trial name
- NCT02993783
- Testing
- Vedolizumab
- Where
- 15 sites in United States, Belgium and 3 more
- Volunteers
- 17 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Graft Versus Host Disease
Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
This trial designed to evaluate the toxicity and efficacy of tocilizumab in the treatment of steroid refractory acute graft versus host disease (GVHD).
- Trial name
- NCT01475162
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Medical College of Wisconsin
Cardiac Arrest
Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
The major goal of this project is to determine whether the use of physiologic doses of corticosteroids will decrease time to shock reversal, alters the inflammatory cascade, and alters microcirculatory flow in post-cardiac arrest…
- Trial name
- NCT00676585
- Testing
- Normal Saline, Hydrocortisone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Graft Versus Host Disease
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
The participant is invited to take part in this study because they have chronic Graft versus Host Disease (cGVHD) that is not responding to standard treatment with steroids.
- Trial name
- NCT01954979
- Testing
- Abatacept
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Beth Israel Deaconess Medical Center
Steroid-Refractory Acute Graft Versus Host Disease
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
The study is designed as an open-label, single arm Phase III, multicenter trial to evaluate the efficacy and safety of T-Guard treatment in patients with Steroid-Refractory acute Graft versus Host Disease (SR-aGVHD).
- Trial name
- 1802 (NCT04128319)
- Testing
- T-Guard
- Where
- 24 sites in United States
- Volunteers
- 3 people
- Sponsor
- Xenikos
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
- Trial name
- NCT02953678
- Testing
- Ruxolitinib, Prednisone or methylprednisolone
- Where
- 38 sites in United States
- Volunteers
- 71 people
- Sponsor
- Incyte Corporation
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Graft vs Host Disease
A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
This clinical trial will study the safety and efficacy of using the drug Zemaira, an Alpha 1-Antitrypsin (AAT) medication (also known as an Alpha1-Proteinase Inhibitor [Human]) for the treatment of steroid refractory GVHD.
- Trial name
- NCT01700036
- Testing
- Alpha-1-Antitrypsin (AAT)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acute Graft Versus Host Disease
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
The study was an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days…
- Trial name
- NCT03491215
- Testing
- Ruxolitinib
- Where
- 19 sites in Belgium, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
This is a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab in comparison with placebo in reducing Oral Corticosteroid (OCS) use in subjects with severe refractory asthma.
- Trial name
- NCT01691508
- Testing
- Mepolizumab, OCS (prednisone/prednisolone)
- Where
- 47 sites in United States, Australia and 8 more
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Steroid Refractory Acute Graft Versus Host Disease
Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease
This is a single-arm, open-label, multicenter study of the efficacy of UVADEX® (methoxsalen) Sterile Solution in conjunction with THERAKOS® CELLEX® Photopheresis Systems (ECP) in pediatric participants with steroid-refractory…
- Trial name
- NCT02524847
- Testing
- Methoxsalen, Extracorporeal Photopheresis (ECP)
- Where
- 32 sites in United States, Austria and 6 more
- Volunteers
- 29 people
- Sponsor
- Therakos, Inc., a Mallinckrodt Company
Graft vs Host Disease
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
This study was been conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult participants with chronic graft versus host disease (cGVHD).
- Trial name
- NCT02841995
- Testing
- Belumosudil (KD025)
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Kadmon, a Sanofi Company
Meniere's Disease
Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease
This trial aims to compare transtympanic steroids against the standard treatment (transtympanic gentamicin) in refractory unilateral Meniere's disease.
- Trial name
- NCT00802529
- Testing
- Methylprednisolone, Gentamicin
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD).
- Trial name
- NCT04910152
- Testing
- BRD4 Inhibitor PLX51107
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hannah Choe, MD
Chronic Graft-versus-host-disease
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following…
- Trial name
- NCT02340676
- Testing
- Extracorporeal Photopheresis (ECP), Interleukin-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Graft Versus Host Disease
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
The purpose of this research study is to determine the safety of IL-2 and the highest dose of this drug that can be given safely to people with chronic graft versus host disease (GVHD).
- Trial name
- NCT00529035
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Graft Versus Host Disease
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.
- Trial name
- iNTEGRATE (NCT02959944)
- Testing
- ibrutinib, Prednisone
- Where
- 102 sites in United States, Australia and 13 more
- Volunteers
- 193 people
- Sponsor
- Pharmacyclics LLC.
Chronic Graft vs. Host Disease, Graft vs Host Disease
Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD
Background: Some allogeneic stem cell transplant recipients get acute graft-versus-host disease (GVHD). They always get steroids as the first treatment, but this may not work.
- Conditions
- Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
- Trial name
- NCT02322190
- Testing
- Extracorporeal Photopheresis (ECP), Methoxsalen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)